Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Theravance Biopharma will share clinical insights on norepinephrine reuptake inhibitor ampreloxetine at AAS 2025

Written by | 1 Nov 2025

Theravance Biopharma, Inc announced that it will be participating at the 36th International Symposium on the Autonomic Nervous System, organized by the American Autonomic Society (AAS), taking place November 5-8, 2025, in Clearwater… read more.

Alexion to highlight advances across its rare neurology portfolio at AANEM and MGFA 2025

Written by | 31 Oct 2025

Alexion, AstraZeneca Rare Disease, will deliver 18 presentations, including four oral presentations, from its leading rare neurology portfolio at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)… read more.

MetaVia will share clinical results for GPR119 agonist Vanoglipel at AASLD Liver Meeting 2025

Written by | 29 Oct 2025

MetaVia Inc a clinical-stage biotechnology company focused on transforming cardiometabolic diseases,  announced that an abstract highlighting data on Vanoglipel (DA-1241), a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, has… read more.

Novartis will share late-breaking Phase 3 ianalumab results and CAR-T data at ACR Convergence 2025

Written by | 28 Oct 2025

Novartis announced plans to present data from 27 company- or investigator-sponsored abstracts across its Immunology portfolio and pipeline at the 2025 American College of Rheumatology (ACR) Convergence. Data… read more.

Sobi will share clinical findings for NASP, pacritinib and emapalumab-lzsg at ACR Convergence 2025

Written by | 27 Oct 2025

Sobi global biopharmaceutical company dedicated to delivering innovative treatments for patients with rare disease, will be presenting new data across its immunology portfolio at the annual American College… read more.

Galapagos to present new data on TYK2 inhibitor GLPG3667 at ACR Convergence 2025

Written by | 26 Oct 2025

Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG3667, currently in two Phase 3-enabling… read more.

Akebia Therapeutics to share latest clinical and real-world findings for Vafseo at ASN Kidney Week 2025

Written by | 24 Oct 2025

Akebia Therapeutics®, Inc., announced that it will present data at the American Society of Nephrology Kidney Week 2025 (ASN Kidney Week), which will take place in Houston, TX from November 5-9, 2025. ASN… read more.

MetaVia to share latest research on DA-1726 for obesity and metabolic disorders at ObesityWeek 2025

Written by | 23 Oct 2025

MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, announced that two abstracts highlighting data on DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as… read more.

Moderna to share latest research across its mRNA vaccine portfolio, including influenza, RSV and COVID-19, at IDWeek 2025

Written by | 21 Oct 2025

Moderna, Inc. (announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. The details of the presentations… read more.

Gilead Sciences to present new antiviral research across HIV, hepatitis and respiratory viruses at IDWeek 2025

Written by | 20 Oct 2025

Gilead Sciences, Inc. will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV,… read more.

Nuvectis Pharma will present clinical and preclinical findings for NXP900 at AACR-NCI-EORTC 2025

Written by | 19 Oct 2025

Nuvectis Pharma Inc, a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology,… read more.

Actinium Pharmaceuticals to share new radiotherapy research on ATNM-400 across solid tumors at AACR-NCI-EORTC 2025

Written by | 18 Oct 2025

Actinium Pharmaceuticals, Inc.), a leader in the development of differentiated targeted radiotherapies  announced that the first-ever preclinical data from its ATNM-400 program in non-small cell lung cancer (NSCLC)… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.